sharon osbourne, chelsea handler and elon musk have all talked about publicly taking ozempic or wego v. it's a global phenomenon reaching millions on social media apps, including tiktok. but it's not without controversy including possible side effects, high prices on the company's lobbying for seen criticism around the world. in some cases patients might need to take the drugs indefinitely to avoid regaining the weight. the chief executive says obesity is a disease and think the company will learn from its growing number of patients. >> my personal view is that we will also feel that taste -- patients are -- much different and will be different. so there will have to be a portfolio of inventions. francine: i travel to the firm's headquarters in copenhagen, denmark. i asked lars about the global sensation, how he's navigating the company's meteoric rise in the sweeping changes they could bring across a range of industries. thank you so much for being on bloomberg with us. lars: thank you for having me. francine: after decades of research you find a molecule that changes everything in

sharon osbourne, chelsea handler, and elon musk have all publicly talked about taking ozempic or wegovy, and they've had further backing from oprah winfrey. it's a global phenomenon, reaching millions on social media apps, including tiktok. but it's not without controversy, including possible side effects, high prices, and the company's lobbying efforts receiving criticism around the world. and in some cases, patients might also need to take the drugs indefinitely to avoid regaining the weight. chief executive lars fruergaard jorgensen says obesity is a disease and thinks the company will learn from its growing number of patients. lars: when i ask the scientists, they say the priority and mechanism will tell you that it's chronic treatment. my personal view is that we will also learn that patients are much different, and there will be different avenues, so, we will have to build a portfolio of interventions. francine: on this episode of "leaders with lacqua," i travel to the firm's headquarters in copenhagen, denmark. i asked lars fruergaard jorgensen about the global sensation, how he